Total : 1 View more »
Inovio Biomedical Corporation (NYSE Amex: INO), a leader in DNA vaccine design, development and delivery, announced that its board of directors elected David J. Williams, former chairman and CEO of Sanofi Pasteur, the vaccine business of Sanofi-Avent
http://www.pharmiweb.com/pressreleases/pressrel.asp?ROW_ID=9125
Total : 44 View more »
Oct 21, 2009 (SmarTrend(R) Spotlight via COMTEX) --
SmarTrend, our proprietary pattern recognition system, called a Downtrend for Inovio Biomedical (AMEX:INO) on September 14, 2009 at $1.81.
Since then, Inovio Biomedical has returned 21% as of today's recent price of $1.43. Want to profit from these alerts?
Go to www.mysmartrend.com now for a FREE two-week trial.
Write to Chip Brian at cbrian@tradethetrend.com
---------------------------------------------------------------------------------------------
SmarTrend analyzes over 5,000 securities simultaneously throughout the trading day and provides its subscribers with trend change alerts in real time. To get a free trial of our trading calls and maximize your trading results, please visit http://www.TradeTheTrend.com.
Get exclusive, actionable insight into how the market is expected to trend prior to market open with our free morning newsletter. Sign up at: http://www.TradeTheTrend.com/signup.html
Tags: amex biomedical market profit securities trial
Companies: Inovio Biomedical Corp (INO)
SAN DIEGO, Oct 26, 2009 (BUSINESS WIRE) --
Inovio Biomedical Corporation (NYSE Amex: INO), a leader in DNA vaccine design, development and delivery, announced that its board of directors elected David J. Williams, former chairman and CEO of Sanofi Pasteur, the vaccine business of Sanofi-Aventis Group, and Keith H. Wells, a senior member of the Biologics Consulting Group and former director of vaccine development for The Salk Institute, to the board.
David J. Williams retired in 2008 as chairman & CEO of Sanofi Pasteur, the vaccines business of the Sanofi-Aventis Group. His leadership moved the company from a niche vaccine business to the global leader in vaccine development, production and sales, with revenues of more than $6 billion in 2007. Under his guidance, more than a billion doses of lifesaving vaccines were administered to more than 500 million people around the world each year, representing more than 25% of the global vaccine market. During his tenure the company licensed more than 30 new vaccines and launched hundreds of business development deals.
For the past 20 years, Keith H. Wells, a senior member of Biologics Consulting Group, has overseen all facets of vaccine development including process development and validation, manufacturing operations, and U.S. and European regulatory strategy for several international companies. He has directed vaccine development at Acambis, PLC, Oravax, and The Salk Institute, and provided R&D support to vaccine manufacturing at Merck & Co. He has a Ph.D. in microbiology and immunology from State University of New York Health Science Center at Syracuse.
Dr. J. Joseph Kim, president & CEO of Inovio, said: "These two business leaders each have multiple decades of experience leading and executing the development and commercialization of cutting-edge vaccine technology and important new vaccines. Their expertise will be invaluable to Inovio as we advance a new generation of vaccines - DNA vaccines delivered using the potency-enhancing capabilities of electroporation - that are displaying superior results and potential to not only prevent but treat challenging infectious diseases and cancers."
Inovio Biomedical's other board members are Avtar Dhillon, M.D., Inovio's executive chairman; Dr. J. Joseph Kim, Inovio's president & CEO; Simon Benito, former senior vice president of Merck's vaccine division; Morton Collins, general partner of Battelle Ventures; and Ng Tee Khiang, co-founder of Evia Capital Partners and Evia Growth Opportunities.
About Inovio Biomedical Corporation
Inovio Biomedical is focused on the design, development, and delivery of a new generation of vaccines, called DNA vaccines, to prevent and treat cancers and infectious diseases. The company's SynCon(TM) technology enables the design of DNA-based vaccines capable of protecting against both known and new, unknown strains of pathogens such as influenza. Inovio's proprietary electroporation-based DNA vaccine delivery technology has been shown by initial human data to safely and significantly increase gene expression and immune responses. Inovio's clinical programs include HPV/cervical cancer (therapeutic) and HIV vaccines. An IND has been filed for an avian influenza vaccine. Inovio is developing its universal and avian influenza vaccines in collaboration with scientists from the University of Pennsylvania, the National Microbiology Laboratory of the Public Health Agency of Canada, and the NIH's Vaccine Research Center. Other partners and collaborators include Merck, Tripep, University of Southampton, National Cancer Institute, and HIV Vaccines Trial Network. More information is available at www.inovio.com.
This press release contains certain forward-looking statements relating to, among other things, our plans to develop electroporation-based drug and gene delivery technologies and DNA vaccines. Actual events or results may differ from the expectations set forth herein as a result of a number of factors, including uncertainties inherent in clinical trials and product development programs, including but not limited to the fact that pre-clinical and clinical results referenced in this release may not be indicative of results achievable in other trials or for other indications, that results from one study may not necessarily be reflected or supported by the results of other similar studies, that results from an animal study may not be indicative of results achievable in human studies, that clinical testing is expensive and can take many years to complete, that the outcome of any clinical trial is uncertain and failure can occur at any time during the clinical trial process, and that our electroporation technology and DNA vaccines may fail to show the desired safety and efficacy traits in clinical trials; the availability of funding; the ability to manufacture vaccine candidates; the availability or potential availability of alternative therapies or treatments for the conditions targeted by us or our collaborators, including alternatives that may be more efficacious or cost-effective than any therapy or treatment that we and our collaborators hope to develop; whether our proprietary rights are enforceable or defensible or infringe or allegedly infringe on rights of others or can withstand claims of invalidity; the impact of government healthcare proposals and other factors set forth in our Annual Report on Form 10-K for the year ended December 31, 2008, our Form 10-Q for the quarterly period ended June 30, 2009, and other regulatory filings from time to time. There can be no assurance that any product in Inovio's pipeline will be successfully developed or manufactured, that final results of clinical studies will be supportive of regulatory approvals required to market licensed products, or that any of the forward-looking information provided herein will be proven accurate.
SOURCE: Inovio Biomedical Corporation
Investors: Inovio Biomedical Bernie Hertel, 858-410-3101 or Media: Richardson & Associates Jeff Richardson, 805-491-8313
Tags: amex animal annual report biomedical business canada cancer ceo clinical consulting dna executive government health healthcare hiv indiana manufacturer manufacturing market new_york nyse pennsylvania pipeline president product development products research sales science technology trial university vaccine
Companies: Inovio Biomedical Corp (INO)
Oct 27, 2009 (Wall Street Horizon via COMTEX) --
Inovio Biomedical Corp. (INO)
Expected next earnings release: Announcement date: 11/17/2009 - After Market Earnings Quarter: Q3 Announcement Status: Unconfirmed
Tags: biomedical corporate earnings market
Companies: Inovio Biomedical Corp (INO)
Boston, MA, Oct 22, 2009 (M2 PRESSWIRE via COMTEX) --
HearAtLast Holdings, Inc. (PINKSHEETS: HRAL); Inovio Biomedical Corporation (NYSE Amex: INO)
TheWallStreetLeader.com is part of Stock Profiler.US, LLC's News Division. Stock Profiler welcomes investors to sign up at www.stockprofiler.us. to subscribe to our FREE newsletter. Please follow our thread on www.twitter.com at StockProfilerUS
Stock Profiler is pleased to introduce HearAtLast Holdings, Inc. (PINKSHEETS: HRAL) to the investment community. Please visit us at www.stockprofiler.us for more detailed information.
-------------------------------------------
HearAtLast Holdings, Inc. closed at $0.052 Tuesday, trading 315,000 shares.
Company News- October 20, 2009: HearAtLast Pioneers New iSign Direct Marketing Technology
HearAtLast Holdings, Inc. (PINKSHEETS: HRAL) announced yesterday that it will begin a pilot with iSign Media in a new and innovative method of direct marketing.
http://smallcapvoice.com/blog/8-26-09-audio-interview-with-hearatlast-holdings-inc-otcpk-hral/
To read the full news release, go to www.stockprofiler.us, click the Headline Tab, enter the ticker symbol and click the news link.
About HearAtLast
HearAtLast Holdings, Inc. is a Nevada corporation that owns and operates its wholly owned subsidiary of hearing stores co-located within select Wal-Mart stores throughout Canada. Their chain of hearing stores specializes in the sale of digital hearing aids and testing services. The Company is the affordable hearing solution for Canadians, combining the most sought after retail space in North America with convenience and location. For more information please visit www.hearatlast.com.
-------------------------------------------
Inovio Biomedical Corporation closed at $1.48 Tuesday, trading 548,700 shares.
Company News- October 21, 2009: Inovio Biomedical to Present at Investor Conferences
Inovio Biomedical Corporation (NYSE Amex: INO) announced earlier today that the company will present corporate updates at two investor conferences next week.
To read the full news release, go to www.stockprofiler.us, click the Headline Tab, enter the ticker symbol and click the news link.
About Inovio Biomedical Corporation
Inovio Biomedical is focused on the design, development, and delivery of a new generation of vaccines, called DNA vaccines, to prevent and treat cancers and infectious diseases. The company's SynCon technology enables the design of DNA-based vaccines capable of protecting against both known and new, unknown strains of pathogens such as influenza. Inovio's proprietary electroporation-based DNA vaccine delivery technology has been shown by initial human data to safely and significantly increase gene expression and immune responses. Inovio's clinical programs include HPV/cervical cancer (therapeutic) and HIV vaccines. An IND has been filed for an avian influenza vaccine. Inovio is developing its universal and avian influenza vaccines in collaboration with scientists from the University of Pennsylvania, the National Microbiology Laboratory of the Public Health Agency of Canada, and the NIH's Vaccine Research Center. Other partners and collaborators include Merck, Tripep, University of Southampton, National Cancer Institute, and HIV Vaccines Trial Network. More information is available at www.inovio.com.
-------------------------------------------
The companies that are discussed in this opinion have not approved the statements made in this opinion. This opinion contains forward-looking statements that involve risks and uncertainties. This material is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. TheWallStreetLeader.com is a division of Stock Profiler.US, LLC's News Division, which includes but is not limited to www.stockprofiler.us, www.fastmoneytalk.com, www.markettelegraph.com, www.associatesfortune.com and www.daytradersdigest.com. Stock Profiler.US, LLC has been compensated for services rendered; Stock Profiler.US, LLC is not a licensed broker, broker dealer, market maker, investment banker, investment advisor, analyst or underwriter.
Please consult a broker before purchasing or selling any securities mentioned herein. To view full disclaimers and terms of use, go to www.stockprofiler.us.
Keywords: Small Cap Investments, Investor Relations, I/R Services, Investment Tools, Stock Profiles, Stock Market Quotes, Media Coverage, Google Finance, Google Analytics, Google, Yahoo Finance, Yahoo, MSNBC, Search Engine, AOL Finance, AOL, Businesswire, PR Newswire Alphatrade, Comtex, Comtex A, Comtex B, Zacks, Real Trader, Market Wire, Market News Publications, AFX U.K., Future World, JAGNotes.com, Internetwire, EURO PR News, First Call, PrimeZone, U.S. News, Forbes, Track Notes, Hearing Loss, Hearing Aids, Medical Devices, Wal-Mart
CONTACT: TheWallStreetLeader.com e-mail: info@stockprofiler.us WWW: http://www.thewallstreetleader.com
((M2 Communications disclaims all liability for information provided within M2 PressWIRE. Data supplied by named party/parties. Further information on M2 PressWIRE can be obtained at http://www.presswire.net on the world wide web. Inquiries to info@m2.com.
Tags: advisor aids amex biomedical broker canada cancer clinical community corporate dealer direct marketing dna e-mail euro finance health hiv indiana investment investment opinion market marketing media medical national cancer institute nevada north america nyse pennsylvania pilot research retail securities small cap technology track trial university vaccine web
Companies: Hear AtLast Holdings Inc (HRAL), Inovio Biomedical Corp (INO)
Total : 30 View more »
Inovio Biomedical Corporation collects information from our website users, subscribers and other customers. In this section of our Privacy Statement, we describe the type of information we collect and how we use it to provide better services to our customers.
Therapeutic DNA Vaccine Company Inovio Biomedical Corp. Announces ...SAN DIEGO -- Inovio Biomedical Corp. (AMEX:INO), a leader in enabling the development of therapeutic DNA vaccines for cancers and infectious diseases using ...
Amgen (AMGN) (Jobs) Shares Drop, Hit by More Anemia-Drug Fallout NEW YORK, May 15 (Reuters) - Another setback for Amgen Inc.'s anemia-drug franchise sent shares of the No. 1 biotechnology company spiraling down as much as 6.
The application is designed to permit initial clinical testing of Tripep's proprietary DNA vaccine, ChronVac-C(R), administered using Inovio's MedPulser(R) DNA Delivery System. This combination is designed to activate a T-cell response capable of clearing hepatitis C virus.
http://www.pharmacychoice.com/News/article.cfm?Article_ID=43141
Total : 13,800 View more »
Inovio Biomedical Corporation is a late stage biomedical company focused on building an oncology franchise based on its proprietary electroporation therapy.
Inovio Biomedical Corporation. The Group's principal activity is to develop and commercializing novel medical therapies to cure diseases with critical unmet treatment needs using ...
http://www.corporateinformation.com/Company-Snapshot.aspx?cusip=45773H102
Inovio Biomedical Corporation is a late stage biomedical company focused on building an oncology franchise based on its proprietary electroporation therapy.
Inovio Biomedical Corporation Company Profile - View the latest news, market research, credit research, and investment research on Inovio Biomedical Corporation San Diego CA United ...
http://www.alacrastore.com/company-snapshot/Inovio_Biomedical_Corporation-1088257